CliffBio
small molecule

INLURIYO

IMLUNESTRANT TOSYLATE

Loss of exclusivityJuly 2039latest FDA-listed patent expiry
CompanyELI LILLY AND CO

Drug detail

Brand nameINLURIYO
Active ingredientIMLUNESTRANT TOSYLATE
StrengthEQ 200MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2025
Marketing statusRX

Listed patents

PatentExpiresType
11117902July 2039substance, product
10654866July 2039substance, product

Regulatory exclusivity

CodeExpires
NCESeptember 2030

More from ELI LILLY AND CO

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

INLURIYO patent cliff — loss of exclusivity July 2039 | CliffBio